Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 126Cisplatin 48Cetuximab 46Nivolumab 36Carboplatin 33Paclitaxel 28Fluorouracil 26Docetaxel 17Cyclophosphamide 12avelumab 11Radiotherapy 11cemiplimab 10atezolizumab 10durvalumab 9Ipilimumab 8spartalizumab 7fludarabine 7budigalimab 7Gemcitabine 7Capecitabine 7tremelimumab 6lenvatinib 6Pemetrexed 6130-nm albumin-bound paclitaxel 6epacadostat 5Fulvestrant 5zimberelimab 4tislelizumab 4Trastuzumab 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Carcinoma of Head and Neck × TAK-981 × Clear all
NCT04065555 2022-07-29

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Presage Biosciences

Phase EARLY_PHASE1 Completed
12 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡